TP53 and neoplasm: It is, therefore, imperative that targeting the p53 pathway is incorporated into an active immunotherapy approach for maximal therapeutic benefits, which certainly relies on our better comprehension of the specific mechanisms/pathways through which p53 actively regulates host immune responses and the immunological landscape of the tumor microenvironment.